INTRAVENOUS VERSUS ORAL CLOMIPRAMINE IN OBSESSIVE COMPULSIVE DISORDER

静脉注射与口服氯米帕明治疗强迫症的比较

• 批准号: 6276243
• 负责人: LORRIN M. KORAN
• 金额: $ 4.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276243
• 关键词: body temperature; clinical research; clinical trials; clomipramine; drug administration routes; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; mental disorder chemotherapy; obsessive compulsive disorder; oral administration

This double-blind study of 20 patients with obsessive-compulsive disorder (OCD) tests the hypothesis that; 1) Intravenous pulse loading of clomipramine (150 mg Day 1, 200 mg Day 2) will produce a larger decrease in symptoms of OCD than will identical oral doses; and 2) the larger the drop in core body temperature produced by the first dose of clomipramine, the more likely the patient's OCD symptoms will respond.

这项对20名强迫症患者进行的双盲研究 强迫症（OCD）测试的假设，1）静脉脉冲负荷 氯丙咪嗪（150 mg第1天，200 mg第2天）将产生较大的 减少强迫症的症状比将相同的口服剂量;和2） 第一次注射时， 氯丙咪嗪，病人的强迫症症状就越有可能得到缓解。